Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the Outcome of Community-onset Bacteremic Urinary Tract Infections

Journal of Microbiology, Immunology and Infection

Volumn 43, Issue 3, 2010, Pages 194-199

  Yang, Ya Sung ^a   Ku, Chih Hung ^b   Lin, Jung Chung ^a   Shang, Shih Ta ^a,c   Chiu, Chun Hsiang ^a   Yeh, Kuo Ming ^a   Lin, Chu Chun ^b   Chang, Feng Yee ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAO YUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

bacteremia; community; extended spectrum lactamase; urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT; EXTENDED SPECTRUM BETA LACTAMASE;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIURIA; COMMUNITY ASSESSMENT; COMMUNITY CARE; CONTROLLED STUDY; DRUG COST; DRUG USE; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; INFECTION RISK; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; INTENSIVE CARE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MIDDLE AGED; RISK FACTORS; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS;

EID: 77953097553     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1684-1182(10)60031-X     Document Type: Article

References (21)

1. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32 (2001) 1085-1089
2. Jacoby G.A., and Medeiros A.A. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 35 (1991) 1697-1704
3. th edition (2000), Churchill Livingstone, Philadelphia 2294-2310
4. th edition (2008), Clinical and Laboratory Standards Institute, Wayne, PA M2-A10
5. th edition (2006), Clinical and Laboratory Standards Institute, Wayne, PA M7-A8
6. th Informational Supplement. M100-S17
7. Leibovici L., Greenshtain S., Cohen O., and Wysenbeek A.J. Toward improved empiric management of moderate to severe urinary tract infections. Arch Intern Med 152 (1992) 2481-2486
8. Leibovici L., Greenshtain S., Cohen O., Mor F., and Wysenbeek A.J. Bacteremia in febrile patients. A clinical model for diagnosis. Arch Intern Med 151 (1991) 1801-1806
9. Rodriguez-Bano J., Navarro M.D., Romero L., Martínez-Martínez L., Muniain M.A., Perea E.J., et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42 (2004) 1089-1094
10. Colodner R., Rock W., Chazan B., Keller N., Guy N., Sakran W., et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23 (2004) 163-167
11. Kang C.I., Cheong H.S., Chung D.R., Peck K.R., Song J.H., Oh M.D., et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 27 (2008) 85-88
12. Friedman N.D., Kaye K.S., Stout J.E., McGarry S.A., Trivette S.L., Briggs J.P., et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137 (2002) 791-797
13. Rodriguez-Bano J., Navarro M.D., Romero L., Muniain M.A., de Cueto M., Ríos M.J., et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 43 (2006) 1407-1414
14. Mirelis B., Navarro F., Miro E., Mesa R.J., Coll P., and Prats G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis 9 (2003) 1024-1025
15. Laupland K.B., Church D.L., Vidakovich J., Mucenski M., and Pitout J.D. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 57 (2008) 441-448
16. Rodriguez-Bano J., Lopez-Cerero L., Navarro M.D., Diaz de Alba P., and Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 62 (2008) 1142-1149
17. Valverde A., Grill F., Coque T.M., Pintado V., Baquero F., Cantón R., et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 46 (2008) 2796-2799
18. Ho P.L., Wong R.C., Chow K.H., Yip K., Wong S.S., and Que T.L. CTX-M type beta-lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non-hospitalized children and adults. J Microbiol Immunol Infect 41 (2008) 428-432
19. Moor C.T., Roberts S.A., Simmons G., Briggs S., Morris A.J., Smith J., et al. Extended-spectrum beta-lactamase (ESBL)-producing entero-bacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect 68 (2008) 355-362
20. Apisarnthanarak A., Kiratisin P., and Mundy L.M. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol 29 (2008) 671-674
21. Pitout J.D., and Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8 (2008) 159-166